American Hospital Supply Corporation

Amylin Pharmaceuticals, Inc.

Candace X Moore

Garth J Cooper

Gustaf O Arrhenius

Michael L Goldstein

Non-insulin dependent, or type 2, diabetes mellitus in a patient is treated by administering to the patient a hypoglycemic agent that enhances plasma concentrations of amylin and a therapeutically effective amount of an amylin antagonist. Hypoglycemic agents which enhance plasma concentrations of amylin can be sulfonylureas such as glibenclamide and tolbutamide. Amylin antagonists can be amylin 8-37 and CGRP 8-37. Administration of the amylin antagonist in conjunction with the hypoglycemic agent also enhances the blood glucose lowering effects of the hypoglycemic agent.

Hypoglycemics

Latent heat storage and supply system and method in which a body of crystallizable phase change material and a separate body of a special crystallization nucleator for the phase change material are associated for heating as a unit to melt the phase change material, for cooling to bring the molten phase change material to supercooled condition in which heat is stored as latent heat of crystallization and thereafter for transferring a controlled portion of the nucleator into the body of phase change material to induce crystallization and release of latent heat of crystallization. The special nucleator includes a component which, after the heating and cooling steps, will contain crystals for nucleating the phase change material and which has a solubility in the phase change material such that the controlled portion added to the body of phase change material will dissolve in that body during the heating step.

Growing community of inventors

San Diego, CA, United States of America

Candace X Moore